Drug development: longer-lived proteins
Protein therapeutics represent a powerful class of clinically approved drugs for the prevention and treatment of various diseases. Once administered, the biological fate of protein therapeutics is governed by the body's various complex biochemical and biophysical clearance mechanisms, several of which may decrease the drug's circulation time and efficiency. In this tutorial review, we introduce the concepts of physiological protein clearance from the body, and describe several chemical modification and protein engineering approaches used to improve the life span of administered protein therapeutics.
Keywords: Neonatal Fc-Receptor ; In-Situ Growth ; Albumin Domain Antibodies ; Chronic Hepatitis-C ; Half-Life ; Fusion Protein ; Human Igg1 ; Improved Pharmacokinetics ; Monoclonal-Antibodies ; Interferon-Alpha
Record created on 2012-02-15, modified on 2016-08-09